FOLFOX, Nivolumab, Trastuzumab Fares Best in ERBB2-Positive Gastric Cancer
A chemotherapy-containing regimen appears more effective than a chemotherapy-free regimen as first-line therapy for ERBB2-positive gastric cancer.
Diagnosis & Disease Information
Eradication of H Pylori Infection Reduces Risk for Gastric Cancer
A team of researchers investigated the long-term effects of eliminating H pylori infection in patients at high risk for gastric cancer.
BRCA1/2 Variants Associated With More Cancers Than Previously Thought
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
LNR Tied to Outcome of Adjuvant Chemo in Locally Advanced Gastric Cancer
Patients with lymph node ratios of 9% or higher had better overall survival when they received adjuvant chemotherapy.
Can Aspirin Prevent Gastric Cancer?
New research suggests aspirin may lower the risk for gastric adenocarcinoma in women but not in men.
Nivolumab Prolongs PFS, Not OS in Advanced Gastric/GEJ Cancer
The median overall survival was 17.45 months in the nivolumab arm and 17.15 months in the placebo arm.
Trastuzumab Deruxtecan Improved OS, ORR in HER2+ Gastric/GEJ Adenocarcinoma
The updated results are from a median survival follow-up of 18.5 months and 133 overall survival events.
Could Immunotherapy Delay, Eliminate Surgery in Gastric/GEJ Cancer?
About 59% of patients achieved a pathologic complete response.
Gut Microbiome, SNPs May Help Predict Nivolumab-Induced Toxicity
Host-related biomarkers might predict toxicities associated with nivolumab treatment in patients with advanced gastric cancer
No Benefit With Pembrolizumab Plus Chemo in PD-L1+ Gastric/GEJ Cancer
The addition of pembrolizumab to chemotherapy did not improve progression-free or overall survival.
- Loading...
Loading...
Next post in ASCO GI 2022
Loading... 
Loading...